地夫可特在中国上市了吗？好购买吗？

Deflazacort is a glucocorticoid drug, and its active metabolite exerts anti-inflammatory and immunosuppressive effects by activating glucocorticoid receptors. The drug relieves the inflammatory response by inhibiting the release of inflammatory mediators, reducing immune cell activity and regulating gene expression. At present, deflazacort has not yet received marketing approval from the Chinese Food and Drug Administration, formal purchasing channels are limited, and it has not been included in the national medical insurance catalog. This article will provide a detailed explanation of these three key issues to help patients understand the current accessibility of deflazacort in China.

Is deflazacort available on the market in China?

As of now, it has not received marketing approval from the China National Medical Products Administration, which means that the drug cannot be sold and used through formal domestic channels.

Approval status

A search of public information from the Drug Evaluation Center of the State Food and Drug Administration shows that deflazacort has not yet submitted a new drug marketing application or obtained an import drug registration certificate. Domestic pharmaceutical companies have no record of approval of relevant generic drugs.

Clinical Usage

Under special circumstances, individual medical institutions may introduce small quantities through temporary import procedures. This situation requires certain conditions to be met, such as treatment necessity, no alternative medicine, single patient use, etc., and a complex approval process needs to be completed.

Because it has not been officially approved, the clinical application of deflazacort in China is strictly restricted, and patient access is very limited.

Is deflazacort easy to buy?

Limited by the fact that it has not been approved for marketing, the accessibility of deflazacort in China is low, and it is difficult for ordinary patients to obtain it through formal channels.

Formal access methods

There are currently only two legal ways to obtain it: one is through a special application from a tertiary hospital with overseas drug procurement qualifications; the other is for the patient to go abroad and purchase it with a prescription in a listed country. Both approaches present many limitations and difficulties.

Informal channel risks

Some patients may try to purchase through personal online channels. This method has greater risks, such as the quality of the medicine cannot be guaranteed, the transportation conditions are not compliant, and it may be suspected of smuggling and illegality. What is more serious is the inability to obtain professional medication guidance.

From the perspective of drug safety and legal compliance, it is not recommended to obtain unapproved drugs through informal channels. Patients should give priority to alternative treatment options that are already on the market in China.

Is deflazacort included in the national medical insurance?

Since it has not yet obtained marketing authorization, deflazacort is naturally not included in the national medical insurance drug catalog, and patients must bear the cost of treatment entirely at their own expense.

Conditions for inclusion in medical insurance

The National Medical Insurance Catalog only includes drugs that have been approved for marketing in the country. Drugs need to pass multi-dimensional evaluations such as safety, effectiveness, and economics, and can be included after undergoing a strict review process.

Cost Burden

The price of deflazacort, which is obtained through special channels, is usually high and cannot be reimbursed, which puts great financial pressure on patients who require long-term medication.

If deflazacort is approved for marketing in China in the future, it will have the opportunity to enter the medical insurance negotiation process. But at this stage, patients need to bear the full cost of the medicine out of their own pocket.